Explore the latest developments concerning 5 things to.
New Diabetes Pill Works as Well as Ozempic For Weight Loss, Trial Finds
A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works about as well as injectable semaglutide for people with type 2 diabetes.
Following an experiment conducted over 72 weeks and across 136 sites in 10 countries, a team led by obesity-medicine specialist Deborah Horn of the University of Texas reported that participants lost an average of 9.6 percent of their body weight on the highest dose of the drug.
That's comparable to the roughly 10 to 15 percent loss in body mass commonly seen in people with diabetes taking injectable semaglutide over a similar period.
Related: Breakthrough Diabetes Treatment May Deliver Insulin Through a Skin Cream
New weight loss drug, taken once weekly, leads to 20% weight loss in trial
According to the World Obesity Federation, as of 2024, about 3 billion people around the world were overweight or obese.
To help in the fight against obesity, medications for weight loss have skyrocketed in popularity over the last few years. A 2024 poll found that about one in eight adults have ever taken a glucagon-like peptide-1 (GLP-1) receptor agonist medication, such as Wegovy or Zepbound.
However, not everyone who takes a GLP-1 medication loses weight. Past studies show that as much as 17% of GLP-1 users may be ânon-respondersâ to the medication.
âObesity is a highly complex chronic medical condition,â Liana K. Billings, MD, MMSc, vice chair of research in the Department of Medicine, and director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Illinois, told Medical News Today.
Retro Arcade Game Console Box 20000 Games in 1 Classic Retro Video Game Double Stick Multiplayer Joysticks Saga Arcade Console
The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.
For more detailed information, explore updates concerning 5 things to.
0 Comments